Document is current

Article History

Received: 6 August 2024

Accepted: 2 January 2025

First Online: 8 January 2025

Declarations

:

: This interview study was approved as part of the MESSINA clinical trial by the Institutional Review Boards (IRB)/ethics committees.

: All participants voluntarily consented to be part of this study through informed consent form.

: All participants consented to publication of anonymized data.

: Authors CNH and HF are employees of AstraZeneca and may own stock/stock options. Authors JB, SM, and JR are employees of IQVIA, which received funding from AstraZeneca for the conduct of this study. CS received research funding from AstraZeneca, EsoCap Biotech, Regeneron Pharmaceuticals Inc., Celldex Therapeutics, Adare Pharmaceuticals Inc., International marketing & Communication, S.A., and Dr. Falk Pharma GmbH; received honoraria as consultant and for providing training at AstraZeneca, Laborie/MMS, Medtronic Covidien AG, Menarini Consumer Healthcare, Doctaforum Medical Marketing S.L., Isomed Pharma S.L., and Farma de Colombia SAS. ESD received research funding from Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, and Shire/Takeda; is a consultant for Abbott, Abbvie, Adare/Ellodi, Aimmune, Akesobio, Alfasigma, ALK, Allakos, Amgen, Apollo, Aqilion, Arena/Pfizer, Aslan, AstraZeneca, Avir, Biorasi, Bryn, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, Eupraxia, Dr. Falk Pharma, Ferring, GSK, Gossamer Bio, Holoclara, Invea, Knightpoint, Landos, LucidDx, Morphic, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda, Target RWE, and Upstream Bio; received educational grants from Allakos, Aqilion, Holoclara, and InveaInvea. MER is a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Celldex, Uniquitybio, Santa Ana Bio, EnZen Therapeutics, Bristol Myers Squibb, AstraZeneca, Pfizer, GlaxoSmith Kline, Regeneron/Sanofi, and Guidepoint; has an equity interest in Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Celldex, Uniquitybio, Santa Ana Bio, EnZen Therapeutics, and Allakos; has received royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust) and UpToDate; is an inventor of patents owned by Cincinnati Children’s Hospital.